Laboratory tests for the antiphospholipid syndrome: current concepts

References

• Conley CL, Hartmann RC. A hemorrhagic disorder caused by circulating anticoagulant in patents with disseminated lupus erythe-matosus. J Clin Invest 1952; 31: 621–2.
   Web of Science ®Google Scholar
• Bowie EJ, Thompson JH, Pascuzzi CA, Owen CA. Thrombosis in systemic lupus erythematosus despite circulating anticoagulant. J Lab Clin Med 1963; 62: 416–30.
   PubMed Web of Science ®Google Scholar
• Mc Neil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120–4.
   PubMed Web of Science ®Google Scholar
• Galli M, Comfurius P, Maassen C, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma cofactor. Lancet 1990; 335: 1544–7.
   PubMed Web of Science ®Google Scholar
• Oosting JD, Derksen RH, Bobbink IW, Hackeng TM, Bouma BN, de Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or Protein S: an explanation for their pathogenic mechanism? Blood 1993; 81: 2618–25.
   Google Scholar
• Wisloff F, Jacobsen E, Liestol S. Laboratory diagnosis of the antiphospholipid syndrome. Thromb Res 2003; 108: 263–71.
   Web of Science ®Google Scholar
• Kandiah DA, Krilis SA. Beta2-glycoprotein I. Lupus 1994; 3: 207–12.
   PubMed Web of Science ®Google Scholar
• McNeeley PA, Dlott JS, Furie RA, et al. [32glycoprotein I-dependent anticardiolipin antibodies preferentially bind the aminoterminal domain of [32glycoprotein I. Thromb Haemost 2001; 860: 590–5.
   Web of Science ®Google Scholar
• Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite anti-phosphlipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309–11.
   PubMed Web of Science ®Google Scholar
• Vila P, Hernandez MC, Lopez-Fernandez MF, Battle J. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost 1994; 72: 209–13.
   Google Scholar
• Shi W, Krilis SA, Chong BH, Gordon S, Chesterman CN. Prevalence of lupus anticoagulant in a healthy population: lack of correlation with anticardiolipin antibodies. Aust NZ J Med 1990; 20: 231–6.
   Google Scholar
• Koike T, Sueishi M, Funaki H, Tomioka H, Yoshida S. Anti-phospholipid antibodies and biological false positive test for syphilis in patients with systemic lupus erythematosus. Clin Exp Immunol 1984; 56: 193–9.
   Google Scholar
• Galli M, Finazzi G, Barbui T. Antiphospholipid antibodies: predictive value of laboratory tests. Thromb Haemost 1997; 78: 75–8.
   Google Scholar
• Levine SR, Salowich-Palm L, Sawaya K, et al. IgG anticardiolipin antibody titer >40 GPL and the risk of subsequent thromboocclusive events and death. A prospective cohort study. Stroke 1997; 28: 1660–5.
   Google Scholar
• The Antiphospholipid Antibodies in Stroke Study Group. Clinical and laboratory findings in patients with antiphospholipid antibodies and cerebral ischemia. Stroke 1990; 21: 1268–73.
   PubMed Web of Science ®Google Scholar
• Bick RL, Jakway J, Baker WF Jr. Deep venous thrombosis: prevalence of etiologic factors and results of management in 100 consecutive patients. Semin Thromb Hemost 1992; 18: 267–74.
   Google Scholar
• Hamsten A, Norberg R, Bjorkholm M, De Faire U, Holm G. Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet 1986; 1: 113–15.
   Google Scholar
• Aoki K, Hyashi Y, Hirao Y, Yagami Y. Specific antiphospholipid antibodies as predictive variable in patients with recurrent pregnancy loss. Am J Reprod Immunol 1993; 29: 82–7.
   PubMed Web of Science ®Google Scholar
• Abu-Shakra M, Gladman D, Urowitz MB, Farewell V. Anti-cardiolipin antibodies in systemic lupus erythematosus: clinical and laboratory correlations. Am J Med 1995; 99: 624–8.
   Google Scholar
• Sebastiani GD, Galeazzi M, Tincani A, et al. Anticardiolipin and anti-beta2-GPI antibodies in a large series of European patients with systemic lupus erythematosus: prevalence and clinical associations. Scand J Rheumatol 1999; 28: 344–51.
   PubMed Web of Science ®Google Scholar
• Melk A, Mueller-Eckhardt G, Polten B, Lattermann A, Heine O, Hoffmann O. Diagnostic and prognostic significance of anticardio-lipin antibodies in patients with recurrent spontaneous abortions. Am J Reprod Immunol 1995; 33: 228–33.
   PubMed Web of Science ®Google Scholar
• McNeil HP, Chesterman CN, Krilis SA. Immunology and clinical importance of antiphspholipid antibodies. Adv Immunol 1991; 49: 193–280.
   PubMed Web of Science ®Google Scholar
• Reddel SW, Krilis SA. The anti-phospholipid syndrome. In: Theofilopoulos AN, Bona CA, editors. The Molecular Pathology of Autoimmune Disease, 2nd ed. New York: Taylor & Francis, 2002; 325–52.
   Google Scholar
• Karmochkine M, Cacoub P, Piette JC, Godeau P, Boffa MC. Antiphosphatidylethanolamine antibody as the sole antibody in systemic lupus erythematosus with thrombosis. Clin Exp Rheumatol 1992; 10: 603–5.
   Google Scholar
• Hunt JE, McNeil HP, Morgan GJ, Crameri RM, Krilis SA. A phospholipid r32-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection. Lupus 1992; 1: 75–81.
   Google Scholar
• Roubey RAS, Eisenberg RA, Harper MF, Winfield JB. Anti-cardiolipin autoantibodies recognize [32glycoprotein I in the absence of phospholipid: importance of antigen density and bivalent binding. J Immunol 1995; 154: 954–60.
   PubMed Web of Science ®Google Scholar
• Arnout J, Wittevrongel C, Vanrusselt M, Hoylaerts M, Vermylen J. Beta-2-glycoprotein I dependent lupus anticoagulants form stable bivalent antibody beta2-glycoprotein I complexes on phospholipid surfaces. Thromb Haemost 1998; 79: 79–86.
   Google Scholar
• Sheng Y, Kandiah DA, Krilis SA. Anti-beta 2-glycoprotein I autoantibodies from patients with the `antiphospholipid' syndrome bind to beta 2-glycoprotein I with low affinity; dimerization of beta 2-glycoprotein I induces a significant increase in anti-beta 2-glycoprotein I antibody affinity. J Immunol 1998; 161: 2038–43.
   Google Scholar
• Lutters BC, Meijers JCM, Derksen RHVV, Arnout J, de Groot PG. Dimers of [32-glycoprotein I mimic the in vitro effects of [32-glycoprotein I-Anti- [32-glycoprotein I antibody complexes. J Biol Chem 2001; 276: 3060–7.
   Google Scholar
• Arvieux J, Regnault V, Hachulla E, Darnige L, Roussel B, Bensa JC. Heterogeneity and immunochemical properties of anti- 132 autoanti-bodies. Thromb Haemost 1998; 80: 393–8.
   PubMed Web of Science ®Google Scholar
• Harris EN, Gharavi AE, Boey ML, et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis. Lancet 1983; 26: 1211–14.
   Google Scholar
• Harris EN. Antiphospholipid antibodies. Br J Haematol 1990; 74: 1–9.
   PubMed Web of Science ®Google Scholar
• Gharavi AE, Harris EN, Asherson RA, Hughes GR. Anticardiolipin antibodies isotype: distribution and phospholipid specificity. Ann Rheum Dis 1987; 46: 1–6.
   PubMed Web of Science ®Google Scholar
• Selva-O'Callaghan A, Ordi-Ros J, Monegal-Ferran F, Martinez N, Cortes-Hernandez F, Vilardell-Tarres M. IgA anticardiolipin anti-bodies: relation with other antiphospholipid antibodies and clinical significance. Thromb Haemost 1998; 79: 282–5.
   Google Scholar
• Wong RCW, Wilson RJ, Pollock W, Steele RH, Gillis D. Anti-cardiolipin antibody testing and reporting practices among labora-tories participating in a large external Quality Assurance Program. Pathology 2004; 36: 174–83.
   Google Scholar
• Wong RCW, Gillis D, Adelstein S, et al. Consensus guidelines on anti-cardiolipin testing and reporting. Pathology 2004; 36: 63–8.
   PubMed Web of Science ®Google Scholar
• Tincani A, Allegri F, Sanmarco M, et al. Anticardiolipin antibody assay: a methodological analysis for a better consensus in routine determinations. Thromb Haemost 2001; 86: 575–83.
   PubMed Web of Science ®Google Scholar
• Harris EN, Pierangli SS. Revisiting the anticardiolipin test and its standardization. Lupus 2002; 11: 269–75.
   PubMed Web of Science ®Google Scholar
• Reber G, Arvieux J, Comby E, et al. Multicenter evaluation of nine commercial kits for the quantitation of anticardiolipin antibodies. Thromb Haemost 1995; 73: 444–52.
   PubMed Web of Science ®Google Scholar
• Wong RCW, Favaloro EJ, Pollock W, et al. A multicentre evaluation of the intra-assay and inter-assay variation of commercial and in-house anti-cardiolipin assays. Pathology 2004; 36: 184–92.
   Web of Science ®Google Scholar
• Favaloro EJ, Silvestrini R. Assessing the usefulness of anticardiolipin antibody assays: A cautious approach is suggested by high variation and limited consensus in multilaboratory testing. Am J Clin Pathol 2002; 118: 548–57.
   PubMed Web of Science ®Google Scholar
• Pierangeli S, Gharavi AE, Harris EN. Testing for antiphospholipid antibodies: problems and solutions. Clin Ostet Gynecol 2001; 44: 48–57.
   Google Scholar
• Reddel SW, Krilis SA. Testing for and clinical significance of anticardiolipin antibodies. Clin Diagn Lab Immunol 1999; 6: 775–82.
   PubMedGoogle Scholar
• Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101: 1827–32.
   PubMed Web of Science ®Google Scholar
• Neville C, Rauch J, Kassis J, et al. Thromboembolic risk in patients with high titre anticardiolipin antibodies and multiple antiphos-pholipid antibodies. Thromb Haemost 2003; 90: 108–15.
   PubMed Web of Science ®Google Scholar
• Lewis S, Keil LB, Binder WL, De Bari VA. Standardized measure-ment of major immunoglobulin class (IgG, IgA, and IgM) antibodies to beta2 glycoproteinI in patients with antiphospholipid syndrome. J Clin Lab Anal 1998; 12: 293–7.
   Google Scholar
• Arvieux J, Pouzol P, Roussel B, Jacob MC, Colomb MG. Lupus-like anticoagulant properties of murine monoclonal antibodies to beta2-glycoprotein I. Br J Haematol 1992; 81: 568–73.
   Google Scholar
• Brighton BA, Dai YP, Hogg PJ, Chesterman CN. Microheterogeneity of beta-2 glycoprotein: implications for binding to anionic phospho-lipids. Biochem J 1999; 340: 59–67.
   PubMed Web of Science ®Google Scholar
• Hunt JE, Simpson RJ, Krilis SA. Identification of a region of beta 2-glycorotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity. Proc Natl Acad Sci USA 1993; 90: 2141–5.
   Google Scholar
• Arvieux J, Regnault V, Hachulla E, Darnige L, Berthon F, Youinou P. Oxidation of [32-glycoprotein I ([32GPI) by the hydroxyl radical alters phospholipid binding and modulates recognition by anti-b2GPI autoantibodies. Thromb Haemost 2001; 80: 70–6.
   Google Scholar
• Schlame M, Haller I, Sammaritano LR, Blarick TJ. Effect of cardiolipin oxidation on solid-phase immunoassay for antiphospho-lipid antibodies. Thromb Haemost 2000; 86: 1475–82.
   Web of Science ®Google Scholar
• Merkel PA, Chang Y, Pierangeli SS, Harris EN, Polisson RP. Comparison between the standard anticardiolipin antibody assay and a new phospholipid assay in patients with a variety of connective tissue diseases. J Rheumatol 1999; 26: 591–6.
   Google Scholar
• Lopez-Soto A, Cervera R, Font J, et al. Isotype distribution and clinical significance of antibodies to cardiolipin, phsophatidic acid, phosphatidylinositol and phosphatidylserine in systemic lupus erythe-matosus: prospective analysis in a series of 92 patients. Clin Exp Rheumatol 1997; 15: 143–9.
   Google Scholar
• Brandt JT, Barna LK, Triplett DA. Laboratory identification of lupus anticoagulants: results of the Second International Workshop for Identification of Lupus Anticoagulants. On behalf of the Subcom-mittee on Lupus Anticoagulants/Antiphospholipid Antibodies of the ISTH. Thromb Haemost 1995; 74: 1597–603.
   Google Scholar
• Galli M, Finazzi G, Bevers EM, Barbui T. Kaolin clotting time and dilute Russell's viper venom time distinguish between prothrombin-dependent and beta2-glycoprotein I-dependent antiphospholipid antibodies. Blood 1995; 86: 617–23.
   PubMed Web of Science ®Google Scholar
• Simmelink MJ, Derksen RH, Arnout J, De Groot PG. A simple method to discriminate between beta2-glycoprotein I and prothrombin-dependent lupus anticoagulants. Thromb Haemost 2003; 1: 740–7.
   Google Scholar
• Rosner E, Pauzner R, Lusky A, Modan M, Many A. Detection and quantitative evaluation of lupus circulating anticoagulant activity. Thromb Haemost 1987; 57: 144–7.
   Google Scholar
• Kandiah DA, Krilis SA. Heterogeneity of lupus anticoagulant (LA) antibodies: LA activity in dilute Russell's Viper venom Time and dilute Kaolin Clotting Time detect different populations of antibodies in patients with the antiphospholipid syndrome. Thromb Haemost 1998; 80: 250–7.
   PubMed Web of Science ®Google Scholar
• Derksen RH, Hasselaar P, Blolczfil L, Gmelig Meyling FH, de Groot PG. Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients. Ann Rheum Dis 1988; 47: 364–71.
   Google Scholar
• Arnout J. Antiphospholipid syndrome: diagnostic aspects of lupus anticoagulants. Thromb Haemost 2001; 86: 83–91.
   PubMed Web of Science ®Google Scholar
• Le Querrec A, Arnout J, Arnoux D, et al. Quantification of lupus anticoagulants in clinical samples using antiNGPI and antiprothrom-bin monoclonal antibodies. Thromb Haemost 2001; 86: 584–9.
   PubMed Web of Science ®Google Scholar
• Tripodi A, Chantaragkul V, Clerici M, Mannucci PM. Laboratory diagnosis of lupus anticoagulants for patients on oral anticoagulant treatment. Thromb Haemost 2002; 88: 583–6.
   PubMed Web of Science ®Google Scholar
• Schjetlein R, Sletnes KE, Wisloff F. A quantitative, semi-automated and computer assisted test for lupus anticoagulant. Thromb Res 1993; 69: 239–50.
   Google Scholar
• Sheng Y, Hanly JG, Reddel SW, et al. Detection of `antiphospholipid' antibodies: a single chromogenic assay of thrombin generation sensitively detects lupus anticoagulants, anticardiolipin antibodies plus antibodies binding beta2-glycoprotein I and prothrombin. Clin Exp Immunol 2001; 124: 502–8.
   PubMed Web of Science ®Google Scholar
• Horbach DA, van Oort E, Donders RC, Derksen RH, de Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphos-pholipid antibodies. Thromb Haemost 1996; 76: 916–24.
   Google Scholar
• Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990; 112: 682–98.
   PubMed Web of Science ®Google Scholar
• Martinuzzo ME, Forastiero RR, Carreras LO. Anti-beta glycoprotein 1 antibodies: detection and association with thrombosis. Br J Haematol 1995; 89: 397–402.
   Google Scholar
• Ogasawara M, Aoki K, Matsuura E, Sasa H, Yagami Y. Anti-b2-glycoprotein 1 antibodies and lupus anticoagulant in patients with recurrent pregnancy loss, prevalence and clinical significance. Lupus 1996; 5: 587–92.
   Google Scholar
• Galli M, Luciani D, Bertolini G, Barbui T. Antibeta 2 glycoprotein I, antiprothrombin antibodies and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003; 102: 2717–23.
   PubMed Web of Science ®Google Scholar
• Viard JP, Amoura Z, Bach JF. Association of anti-beta 2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am J Med 1992; 93: 181–6.
   Google Scholar
• Tubach F, Hayem G, Marchand JL, Weber M, Palazzo E, de Bandt M. IgG anti-beta2-glycoprotein I antibodies in adult patients with systemic lupus eryhtematosus: prevalence and diagnostic value for the antiphospholipid syndrome. J Rheumatol 2000; 27: 1437–43.
   Google Scholar